Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZOLADEX · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ZOLADEX 10.8 mg | EXPERIMENTAL | Participants will receive 10.8 mg ZOLADEX on Day 1 and Day 85. |
| Name | Type | Description |
|---|---|---|
| ZOLADEX | DRUG | Participants will receive ZOLADEX as a subcutaneous (SC) injection on Day 1 (Week 1), and Day 85 (Week 12) for a total of 2 treatments. |
Inclusion Criteria: 1. Age and gender: Female participants aged 18 to 55 years, inclusive. 2. Hormone receptor positive (HR+): Either estrogen receptor positive (ER+) or progesterone receptor positive (PR+) breast cancer, defined as 1% to 100% of tumor nuclei are positive for ER or PR via immunohis...
Top 20 of 92 competitors
ZOLADEX is being studied for use in advanced breast cancer, specifically in premenopausal women with hormone receptor-positive (HR+) disease. The investigational treatment is evaluated for its ability to achieve ovarian suppression. It is currently in Phase 1 clinical development and remains an investigational drug, not yet approved for this indication.
ZOLADEX is a small molecule designed to suppress ovarian function in premenopausal women. By inducing ovarian suppression, it aims to reduce estrogen production, which can fuel hormone receptor-positive breast cancer growth. The drug is being studied in patients with advanced and early-stage HR+ breast cancer.
ZOLADEX is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting a Phase 1 clinical trial to evaluate the drug's effects in premenopausal women with breast cancer.
ZOLADEX is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants to evaluate ovarian suppression in premenopausal women with early-stage and advanced HR+ breast cancer.
ZOLADEX is being evaluated in a single Phase 1 clinical trial with the identifier NCT07310420. This trial, which is currently recruiting, aims to assess ovarian suppression following subcutaneous administration of ZOLADEX 10.8 mg in premenopausal women with early-stage and advanced HR+ breast cancer. The study plans to enroll 176 participants in the United States.
ZOLADEX is a brand name for goserelin, a medication used to suppress ovarian function. In the context of this clinical development program, ZOLADEX is being studied as a subcutaneous injection for ovarian suppression in premenopausal women with HR+ breast cancer. The drug is currently in Phase 1 trials.